Across TCGA pan-cancer cohorts, PHAX Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PHAX data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher PHAX Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PHAX expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
COAD, LUSC, and UCEC are the cancer types where PHAX Mutation most reproducibly stratifies survival.